Interpretation guidance for MHRA regulatory considerations for phage therapeutic products

On 4 June 2025, the MHRA published 'Regulatory considerations for therapeutic use of bacteriophages in the UK'. This was in response to recommendations made by the House of Commons Science, Innovation and Technology Committee Inquiry into the 'The Antimicrobial Potential of Bacteriophages'. The MHRA Regulatory Considerations for phage therapeutic products (PTPs) outlines the relevant regulatory route and requirements to use PTPs as licensed or unlicensed medicines. While this guidance provides the necessary information, it is recognized that regulatory information can be inaccessible to academic and small- to medium-sized enterprise developers who are often unfamiliar with the language, terminology and location of such information. The MHRA, in consultation with the Innovate UK Phage Innovation Network, has therefore developed this interpretation to help PTP developers understand what the guidance is saying, and what evidence is required for regulatory assessment of a marketing authorization application. Examples have been included throughout to provide context and as an aid to understanding.

Authors

Institutions

Publication Details

Journal
Microbiology
Published
2025-11-13
DOI
https://doi.org/10.1099/mic.0.001613
Citations
1
Primary Topic
Bacteriophages and microbial interactions
Type
article
Field-Weighted Citation Impact
1.72
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Interpretation guidance for MHRA regulatory considerations for phage therapeutic products

Mark Sutton, Dann Turner, Annette Sansom, Jason Clark et al.
1 citations
Microbiology
Bacteriophages and microbial interactions
1.72
article

Interpretation guidance for MHRA regulatory considerations for phage therapeutic products

Mark Sutton, Dann Turner, Annette Sansom, Jason Clark, Darren Smith, Francesca E. Hodges, Carmen Coxon, Elizabeth Bell, Evelien M. Adriaenssens, Clare Trippett, JJ Edwards, Cath Rees, Josh Jones, Tas Gohir
article en
1 citations

Abstract

On 4 June 2025, the MHRA published 'Regulatory considerations for therapeutic use of bacteriophages in the UK'. This was in response to recommendations made by the House of Commons Science, Innovation and Technology Committee Inquiry into the 'The Antimicrobial Potential of Bacteriophages'. The MHRA Regulatory Considerations for phage therapeutic products (PTPs) outlines the relevant regulatory route and requirements to use PTPs as licensed or unlicensed medicines. While this guidance provides the necessary information, it is recognized that regulatory information can be inaccessible to academic and small- to medium-sized enterprise developers who are often unfamiliar with the language, terminology and location of such information. The MHRA, in consultation with the Innovate UK Phage Innovation Network, has therefore developed this interpretation to help PTP developers understand what the guidance is saying, and what evidence is required for regulatory assessment of a marketing authorization application. Examples have been included throughout to provide context and as an aid to understanding.

MicrobiologyVol. 171(11)
Defence Science and Technology Laboratory (GB), University of Nottingham (GB), University of the West of England (GB), King's College London (GB), Guy's and St Thomas' NHS Foundation Trust (GB), Innovate UK (GB), Centre for Process Innovation (GB), Quadram Institute (GB), Northumbria University (GB), National Institute for Health and Care Excellence (GB), Campden BRI (United Kingdom) (GB), Kelvin Nanotechnology (United Kingdom) (GB), Latinas Contra Cancer (US), National Institute for Biological Standards and Control (GB)
Openalex Percentile: Top 12%
Bacteriophages and microbial interactions
1.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.